top of page

Stevenage, UK based Spur Therapeutics is readying to take its gene therapy for Gaucher disease into phase 3

  • Jul 17, 2024
  • 1 min read

CEO Michael Parini describes how clinical results Spur has seen to date in six patients, with more data to come later this year, has given the company confidence to plan to initiate a phase 3 trial next year.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page